PRINT • ONLINE • EMAIL DELIVERED • LIVE EVENT T HE GOLD STANDARD providing broad coverage and incisive analysis of the issues, events, trends and strategies shaping pharmaceutical business, marketing and sales returns with a robust 2016 lineup designed to meet the needs of our pharmaceutical marketing audience. e The Magazin The Maga zine of Ph armaceut ical Busin ess TOP 50 PH ARMACEU TICAL COM PANIES and Mark eting • me dadnews.c om • Octo ber 2015 • Volume 34 Number 5 • $100 Joe Benko, an retired after Army veteran who rec en a 40-year ca reer as a dra tly an enginee rin fts hepatitis C g company, was diagn man for after dona osed with ting blood bank. Joe su to a loc spects he co a blood tra ntracted the al blood nsfusion wh virus from en he was vaccinations a child, or fro required du m ring the Vie tnam War. After being diagnosed , Joe avoid treatment ed interfero in fear of the n sid associated with the the e effects commonly rap of his friend and neighbo y. At the insistence he went to r, a local cardi a live er 2 • $100showed the dis r specialist for a biops ologist, e 34 Numb y, which ease had ca cirrhosis. used mild 2015 • Volum liver om • April s.c ew dn da S IONS AGENCIE T A IC N U M M O HEALTHCARE C ess eutical Busin of Pharmac ting • me and Marke Joe’s physi cian suggest ed a newly treatment approved calle offer a bette d Harvoni that could r chance of potentially being cured few weeks of treatmen an t, his viral loa d, after a dramaticall y. Three mo d dropped nths after co therapy, the mp vir blood, mean us was undetectable leting in Joe’s ing he was cured. The Magazine of Pharmaceutical Business and Marketing • medadnews.com • February 2015 • Volume 34, Number 1 • $25 AGENDA 2015 A whole new ball game Company of th T e Year The business of marketing pharmaceuticals today would be almost unrecognizable to a visitor from five years ago; the industry’s fate hangs on how industry leaders respond to all this change. By Joshua Slatko [email protected] o an industry insider who magically fell asleep in 2010 and woke up as the ball dropped in Times Square to ring in 2015, the pharmaceutical industry might be nearly unrecognizable. Five years ago the Aﬀordable Care Act had just been passed and signed by the president; today its consequences have ﬂowed out in all directions, transforming the way healthcare is provided and paid for. Five years ago mobile web was just catching on; today it accounts for more than 60 percent of web traﬃc. The pharmaceutical executive of ﬁve years ago would be overwhelmed by all the new audiences, new decision makers, new expectations, new media, new data and sources of information of today; even for those of us who have not been napping for the past ﬁve years, it can all be a little overwhelming. For this year’s Agenda overview, Med Ad News spoke with a long list of industry insiders, the people who have to deal with this sort of tranformational change every day. Here are the trends that they told us would be most important for pharma marketers in 2015. From the perspective of the healthcare consultants at PwC, the changes wrought in the marketplace by ACA and the rise of new provider and payer entities will drive nothing less than a change in the real meaning of value for pharmaceutical companies and their constituencies, leading to a greater focus on real outcomes accompanied by real data. “The shift of risk in selection and payment for therapeutic treatment to various provider entities introduces new variables that the pharmaceutical product industry will need to orient towards, namely quality and total cost of care,” says Warren Skea, principal, PwC. “No T TOP 10 PIPELINES Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers. The Acquisition Game Hum ira du best -selli ring 2014 ng pr escrip remaine d tion med the world icine ’s . Inside he payer as provider is looking for materially different shifts in clinical quality impact and the total cost of care. longer will pharmaceutical product companies’ strategy that focuses on physician directed therapy based on their clinical knowledge and payors processing claims based on their approved cost of treatment analysis, deﬁne and determine their sucTopping the list of crucial developments cess.” Nothing less than a new deﬁnition of valfor pharma marketers in 2015 is the continuing transition in how health services ue through outcomes-based evidence that are provided and paid for. Today’s brand proves such value is what stands between manager is faced with a bewildering ar- success and failure for pharma companies ray of acronyms – the Accountable Care now, Skea suggests. The very deﬁnition of Organization (ACO) and the Integrated payer has begun to radically shift to a vaDelivery Network (IDN) are the two riety of new models that are both consolimost prominent of many – and each of dating and adopting risk for cost (bundles, these has its own unique decision making capitation) and care (quality, outcomes), to processes and value deﬁnitions. Pharma say nothing of employers and consumers companies are having to learn on the ﬂy who are the primary funding sources. And how to deal with all these new decision this shift is driving a corresponding change makers, a process that is causing perhaps in payer expectations. “The payer as provider is looking for the largest single shift in selling strategy materially diﬀerent shifts in clinical qualin the entire history of the industry. The changing marketplace Inside ity impact and the total cost of care, both Amgen AstraZeneca upstream and downstream, as related to Biogen Idec any product therapy,” Skea says. “ProBristol-Myers Squibb viders also want to know which patient Celgene cohorts will receive the greatest impact Gilead Sciences Merck from the day a therapy is authorized, not Novartis after months or years. Determining the Pfizer holistic, incremental, and/or avoidable Roche costs of care, across a broad range of actual operating costs incurred by delivery SALES-FORCE EFFECTIVENESS: systems outweighs the incremental disCHANGE IS THE CONSTANT count that typiﬁes the current state.” So outcome study proof and the docuPharma sales forces continue to evolve, The Ma mentation of cost and quality diﬀerences trying to meet physicians’ information gazine labotheMagazine is going to have to take place in The and survive in a healthcare needs of Pharmaceut of Pha ical by the and ratory of every day clinical delivery where altered environment radically Business rmaceu Marketing • medadnews therapeuSPEC impact ; and a new player life Act real Care of ordable Aff variables the .com • June 2015 tical IAL RE of value enters the sales-force training field. • Volume 34, Number Busine tic performance. “The validity SPECIAL REPORT 3 • $25 PORT ss and — TOP 100 BIOTECHN measured is best spoken for by provider — TO Marke OLOGY COMPANI industry leaders that have the trust and ES ting P 200 stature of peers across their community,” • me MEDIC dadnew Skea says. “This has become necessary to INES individuals s.com with Type avoid the skepticism that can often aclatory Type III SMA, II and non-ambu• Aug company product company-led studies. as well as a reducust 201 tion in medical complications associ5 • Sova ated with the disease. Volum ldi The investigationa DIRECT TO CONSUMER e 34, into sec vaulted HUMAN Num ime is designed to l medicine olesoxThe impact of Viagra’ ber 4 protect the health s most on recent THE MANNY AWARDS: DTC motor nerve cells. of campaign has brand d place • $25 Olesoxime has been managers talking ROARING BACK granted Orphan Medicinal in about the “humanity” of their Product desfull ye its first ignation for treating communications SMA The Manny Awards of 2014 marked the by the ar European Medicines Agency and Orphan 25th year of this event, and strongly the ma on Drug Designation continued traditions while bringing it into by FDA. rket; Roche announced Ha a new era. This shift to provider system deﬁnitions FIRST in December rvo 2014 a deal to acquire YEAR for outcome value has put a premium Dutalys GmbH, NOT a priYOU challe ni is vately held biotech need to upon the productByindustry’s The lead R FATH AFTER company with headAndrew Humphreys nging quarters in Vienna, • [email protected] ing memER’S LAU LAUNC abandon the vertically integrated model phar Austria. Hu maceutic Dutalys H: adnews.com is dedicated to the bers NCHES mira class that was committed to a pre-determined al indu of the intro velopment of fully discovery and destry’s the 20 for standard duced value deﬁnition over to a highly collabornew antibodies based human, bi-speciﬁc for laun during 2013 compoun 15 ative outcome model that is intent upon on their proprietary ch succ have crown sales DutaMab technology. discovering value as an ongoing journey. set a d ess. new antibodies developed The bi-speciﬁc . In this way product companies can more with this platform are designed to provide PATIENT COMMUNITI responsibly convert to risk based contract novel, best-inES: class molecules for By And PATIENT INFLUENCE agreements where outcomes and the data several therapeutic CONTINUES TO RISE rew Hu ﬁelds. This transaction The growth of communities to support them can be trusted and opmphre such as Inspire lights Roche’s leadership further highand PatientsLikeMe, erationalized across the provider com- not on outcomes or value. In an environcoupled with FDA’s ys • and therapeutic antibodies. in developing recent guidance on ment that is aligned around cost-reducmunity.” rew.hum social media in pharma, he prec A conventional bi-speciﬁ point to how patients phre In addition to the consolidation of pro- tion and fee-for-value, winning on price will increasingly c monoclo2012 ipitous [email protected] nal antibody For merit commoditization. to directly pate leads pharma’s assa models is a biotechnologically vider networks into ACO/IDN attention adnews to the nt cliﬀ ulted engineered artiﬁcial and rollout of the federal and state-level brands that are competing with an eﬀec.com protein consisting lion tune of Big Pha of ty fragments of two of to pate up to and new rma wor exchanges, experiments with outcomes- tive generic, there are fewer options to diﬀerent monoclonal antibodies and consequently next nt expiratdrug saleth of pres $53 bil- were app therape THE MANNY AWARDS based reimbursement and the muscle- avoid this margin squeeze, but for many, riatic can bind utic biol jectedhighest tota ions. 201s potentiacription Adminis roved to two diﬀerent antigens. The 26th annual Manny ﬂexing of the leading pharmacy beneﬁts the path forward looks like a business Crohn’sarthritis The DutaMab ogical tration by the U.S Awards 5 repr lly lost high l could ﬁgure technology platform took place on April est , prod esen of since managers to negotiate exclusive deals partner model. As healthcare in the Unit23rd at Pier Sixty time be lost due $44 billithen, with ts the approva total everduring 201. Food and ucts erate to disease, ankylosing for the development varies by allowing he to in New York City U.S. moves away from fee-for-sered States put general biotechnolog , with pharma is continuing plaq of fully human biseve arth (there 4, uting ls by Dru y by the world’s a to exp on in muc however spondy speciﬁ FDA move towards is undergoing will need to largest h sale prower the seco g avai ritis. In re), and ue psorias costs. vice, healthcare downward pressure onarena biotechnology the c antibodies where each arm a re-pharma litis pact less wid , the brunt ired pate s that massiveto the year in 199 e 53 new company, approaches ndthe Uni juve labl of antibody demonstrates Roche. The disease to Swiss as Ormesher of cloespread is exp nts. 6). This, says CEO Davidcord-breaking nile is (mo , M&A more to seve e for ly cycle partnership C trea sales ted pharma and simultaneous high aﬃnity are tiedmore than giant spent aboutand cure.” for challenges erup Rx dru Also con drug ected This the industry. re), axiaulcerati States, idiopath dtme prevention, management and After $8.3 billion on serlook inc., presents both to biot sixty than the not to be 2013 and nts that tion from g grow trib- pediatr the targets, excellent binding against both August 2014 l spo ve colitis Humira ic generating Joryet Patrickdespite perc position, acquisition Taking a similar its role to assert M&A pharma is also ic Crohn’s opportunities stability, and ndyloar continu began new th is valuedfor the Uni facing echnolog ent of 2012 imis the manufacturin (mo California at $235 billion during activity biotech oﬃ Encer of administrative g properties. This good ﬁrm’s es to in four hepatiti a enthesit approve disease thropath derate and value. ted Stat biosimil y dru the sale 2014,dan, Humir leading mar the chief U.S. biotech sector drug prospect process th-quart s Abb surg gs enables (severe) y, and kets s that the treatment of disease produced is-re d in company, notbelieves core, a Quintiles having a lea compamost pharma yet produced e dur “At this more than desp es and ar com that As a $100point, any nisms that revenue marketplace billion mechads the . Hum ing 201 er com Vie’s secolated arththe EU deals result, ite losi in som petition are For that point in commands could not the shift in the at of vendor,” role during to playinthe nies continue ﬁrst-quartime. But three to erod ter 2015. pack 5. ng excl e othe pan nd-qua ritis. for ped ira months later, InterMune’s gen the in Industry conventional bi-speciﬁbe addressed with indianalysts model amongEsbriet the EM y rece a diﬀerent operating “Most conAccordi iatric PATIEN Ad News. Med Ormesher note that sales e $16 erics hav usivity r major was the third con rter c antibodies. mosttold ntly (pirfenidone) M&A Another private company billion A for this was FDA-approve e bee last between three in received2015 repo ng to spec top-selli secu T AD STIL on volume-discounts, priced cycles tracts ﬁare d for6 treat- by iﬁ L NO to ing idiopathic continued on page n fore 2015. During ve years. a acquisition tive in pres Wit year. With 2014 Roche during 2014 pain cally desi new Hum clearanc rt, the The infl RX FOR HEREN expecteh most criptioncasted ated glob2014, theng prescripyear, Hu was that of Sanin the newest cycle, being the ﬁrst year tients with IPF pulmonary ﬁbrosis. Pa- taris Pharma and redu gne PATI CE: ENT the biotech industry gradually lose the patie uence of d to blockbu betw d to ira form e from al sale biologic tion med mira in August. The Copenha-dru Also term ADH ce is anticipated to continue nt con ability phar een to breath as ﬁbers g Eis gen, Denmark-bas s tinue ster biot ma com ERENCE limited, adherenc icine. nounce during injectio reduce ulation ﬁll up their lungs. petitionminus wheeling and ed ai Co. markete of about therapy gen dealing at record ech bran to d resu ﬁrst-half n volu injectio Another biotech acquisition company pioneeredbiopharmaceutical III levels, and therebut phar e problem panies on HBA WOMAN OF , the signiﬁcan thrive ous $12 rs n its proprietary by ma does is part lysts ﬁrms projecting with some ana- during the THE YEAR experiencin the pharma t bios in the ds app injectioAdminis AbbVie .86 billi er- ty trial inve lts from 2015, me. are enco past year was that Roche Locked Nucleic Acid The Healthcare Businesswomen’s of Hum stigatin tered a growth rate of Global Abb nea on VIS n, imil rove g urage things the have a icularly (LNA) /bio about 20 percent Inc. of a Vie anTro- that has ar com r ease d for Humira as a sub role better for the next two years. phos in January 2015 for up Association hosted contributed to an platform projecteprescrip substan tech indu and Results ira in adu g the eﬃUAL-I, a a vari s. its annual Woman of to EUR era of use of industry can to play Since the last time tial grow emerging 470 million. A cuta dem Phase tion niﬁ cacy lt stry - tum The d ety (ada RNA-targeting therapeutics. Year (WOTY) event conthe med do to and at the New York Hilton tinue by vari drug sale was published by this annual report company based privately held biotech new class icine th peri is anti or nec medicine of auto limumab ne- trol cantly lowonstratedpatients This ous s. with safeMidtown on May 14th cent ) Med Ad News two imm rosi of grow led in stem medicines ered Marseille, od. s is that bod indu hav s has the potenuve years ago, 14 of uve France, tial to address une ing, Trophos’ proprietary e stry grow rate annuall the Lau y drug factor alphs from the dis- gained orphitis or patients the dru itis. at hard-to-treat diseases screening platana bee th rate generating biotech top 100 revenue- form generated ’ risk g visio various therapeutic y unti nearly a lysts ton ing Jannched inclass. in a mon anti- regulato blockbu an of unc sigis a new ﬁelds. l 202 ﬁve listing have been entities from that code TRO19622), olesoxime (product rs for drug desin loss. Abb oclonal men more uary 200 the Uni onSantaris’ LNA platform crease ster prod per0. acquired, including t which wav gna Aid of the Vie is being de- covery former top 20 and drug disuveitis certain veloped for spinal investig tion from has ucts e of ﬁrst- ing the China, than 87 3, Hum ted Stat ductivit in rese members Elan engine unites the muscular with Corp. SMA is a company’s pro(purchased by Perrigo tory in-class is used Brazil, countri ira is avai es dur y. A totaarch and and a Hum forms of ational U.S. rare and debilitatingatrophy. prietary LNA chemistry es ﬁ Co.) and Cubwith its highly l of 41 develop recent ist Pharmaceutic genetic specialized across for trea and Aus includin lable in half 201lings are ira. U.S non-inf treatneuromuscular disease als Inc. (bought intrali and new men . targeted g ting most commonly 13 glob drug discovery Merck & Co.) by diagnosed in a. The Japan, the seco 5, follo expecte and EU ectious molecul t proover capabilities to In children. d dur ally app win regu 850,000 prod ar enti Another former top Uni North results with olesoxime Pivotal Phase II didates againstrapidly deliver drug canFor nd pivotal g positive ing seco la100 company ac- toid on, the Americ roved indi pati uct Hum ﬁrstmRNA and microRNA. in SMA demonstud quired since 2013 results ndstrated a beneﬁcial was InterMune arthritisdrug is a and the cationsents uary ira globhalf 201 y. eﬀect on the main- As a result, scientists are able to from Inc. tenance of markete 5, develop al drug candidates -Jun Europe . neuromuscular function (modera for diseases that alm e 201 sales of AbbVie d in diﬃcult, or repo te to for rheu an Stro ost 9 perc 5 inte $6.65 impossible, to target are severe), marnationa billion. rted ng with ent contemporary drug pso- throughU.S. grow on an ope l sale Janing antibodies and platforms includby dou out seco th for rationa s rose small molecules. The LNA platform is major ble-digi nd-qua Humira con l basis. designed to overcome the limitations of derm market t growth rter 2015, tinued earlier antisense 1 MED atol cate and spu siRNA technologies, AD NEW The ogy and gories:across all rred S AUG unique combination in particular via a U.S gast rheu thre ent UST 2015 of small size, high coverin. compos roentero matolog e binding aﬃnity to exp ition and metabolic stabillogy. g y, ity that enables of equival ire dur adalimu this new class of mab matter drug course ent EU ing Dec emb is schedupat1 MED AD NEWS continued on page by Apr in the patent JUNE 2015 er 6 led il 201 majorit is slated 2016. The y of thos to run 8. its e cou ntries M&A activity througho ut the industry is helping the biotechnology world soar to new heights. T T conti nued on page 6 mk16 2016 MEDIA KIT Insid e “In one word EXTRAORDINARY. It has helped me in providing new vision, new thoughts & exclusive ideas.” is the flagship publication of Outcomes, LLC, a marketing and media company built to quench the evolving consumption habits of B to B audiences. –CNS Marketing, Torrent Pharmaceuticals “Great publication! Read it every month.” Twitter: @medadnews @PharmaLive @ChristianeTrue @DanRx Daniel Becker Brand Director Andrew Humphreys Director of Content –Brand Manager, GlaxoSmithKline Facebook: /medadnewsmannyawards /pharmalive Joshua Slatko Contributing Editor “Med Ad News is very useful, particularly the Top 100 lists. I save those for reference.” LinkedIn: Med Ad News PharmaLive Christiane Truelove Contributing Editor –Marketing Director, Sanofi-Aventis, Inc YouTube: youtube.com/pharmalive Med Ad News Audience – 16,500 Key Decision Makers in Pharmaceutical, Biotechnology, Medical Device and Healthcare Communications. Bonus Distribution – 20,000 Influencers Financial Mgmt 112 Financial Mgmt Misc (Media, Marketing Services, R&D, Licensing, IT) Sales/Account Management 378 Sales/Account Management 1494 C-Level (VP & Above) 1000 2000 3000 4000 5000 6000 7000 8000 Print 2480 C-Level (VP & Above) Product/Brand Mgmt/Marketing /Advertising/Promotion 7135 0 2000 2784 524 Business Strategy 6456 Product/Brand Mgmt/Marketing /Advertising/Promotion 0 Misc (Media, Marketing Services, R&D, Licensing, IT) 925 Business Strategy 75 4000 6000 3550 10,533 8000 Bonus Digital 10000 12000 2016 Departments n Sales and Marketing editorial calendar 2O16 n Interactive & Digital Marketing n Medicine Ave n People On The Move february april n Health Outcomes Sales and Marke ting By Med Ad News HEALTHCARE COMMUNICATIONS AGENCY ISSUE TOP 10 PIPELINES s AGENDA 2016 s SALES-FORCE SWEET ‘16 s MEDICAL ADVERTISING HALL OF FAME Ad Close: 1/16/16 Materials Due: 1/23/16 s s Ad Close: 3/09/16 Materials Due: 3/16/16 staff Local market strat egy By Howard Brock design and pullthrough via an integrated app roach to a patient demogra particular geograph phic common to a certain chronic illnesses. very market Boston, Minnesotic market. As the vulnerab populatio is le Customization making national unique, Pittsburgh representa, the Northwest, and social, ns are identified—based of marketing on local cultural, and examples of cial or regional commer- that have more economic determi- messages and tools influential payers. markets nants—preventive less than optimal.strategies Cleveland, and New measures could Boston, in place be companies would Instead, be characterized York, meanwhile, can those or access to treatment providedput When implementing a local from a local market as markets with who need it most. benefit influentia to egy, tools more and messages market stratstrategy that ensures l academic Smaller ACOs customer-facing will need to medical customized based and Miami, Atlanta, teams have the on the dynamics be and Tampa are centers. ing to partner with IDNs might be will- the framework, messages right where markets pharma in physician , tools, companies with local market. Messages in to address adherenc and training s that make sense markets making power have had more decision- unique tighter reimburs e issues based for and organized ement, for example, Through our worktheir markets. are customers lower market demographics. Areason the might be more reimburs Campbell Alliance across the industry, typesmore open to partnerships. socio-economic with while in ement focused, Archeareas where levels, for like these, combined across the inVentiv and our colleagues market with additiona tend to see higher non-adhe example, clinical decisions physicians can make Health organizat considerations l because people rence rates , the messages have determin and ion more account, phymay not be able will be sician, and patient ed focused on clinical their medicine market strategy that applying a local the segmentations, . Resources may to afford tient support messages information. Pabasis for execution form cused on also be fo- in approach across requires an integrated tactics. will be applicabl areas with higher of strategies markets the e and lations. organization that where elderly popudresses all of the Demogra adhas been establishelimited patient support background are phics related to racial of the different unique functional needs Applica Innovative new d. customers and tion of local market conditions are also important, as some tal technologies and influencers. more prevalent channels are opening strategy digiin individuals of a particula Local market strategy the door to new forms of customiz r race. defined Adherence strategies ation and Implementing must be personal- Consider a market archetype outreach. ized, coordina a successful Across the United in which an organized customer ted, and optimized local mar- maceutic ket strategy requires States, many has . Phar- tocol ent healthcare companies to differ- changes over a set of affiliateda treatment prodynamics can make simply al companies cannot afford including the be found, tomer across the organization. throw money to es to which physician offichigh provider The cus- adherenc into every available model must a pharma manufact concentration and not have access. urer does in cities like Pittsburg payer with key customer establish partnerships Instead, e program to see what In this instance, influential academic works. s and an h, the within the ecosystem other influencers should be integrated adherence solution opportunities as well as peer-to-p media medical centers cities like Boston, of a local market. based in Roles, messages munications could eer the more active tion to personali on data and segmentaoffer a solution. com, tools, and digital employers in role of tions—as From a media ze it to the managing their soluwell as product costs in cities like healthcare and access strategies outreach effort then needs patient. The targeting technologstandpoint, improved Seattle, and the tactics—must to be coordinated to ies are able to strictions on pharmac strict re- market be adapted for ideneach patients. avoid overwhelming individua tify likely physicians by environment. eutical promotio found in markets their With And l ns port and like Minneapolis. adherence solutionspatient sup- a manufact the full range of channels at so that when a physician is geography A local market urer’s disposal engaged in healthcare need to aligned is a geographic which market area in needs. to local patient demographics be ing digital messages, mail today—includ- Times, for information in the New York drivers example, it is possible and Pulling all of this messages, phara common business combine to produce companie through requires macy messages, etc.—the tify the individua to idenenvironm s danger to l of creating a reconsider how ent that af- resources fects patient care, white noise effect. exists up an ad propertyas a physician and serve they allocate and coordinate or marketin and reimbursement.prescribing behaviors, and train teams. the effort needs to be optimized Finally, that might be relevant in that g content ing the data to be a city, a region, A local market could Establis moment. Alternatively, see what works by trackor a state, or it hment of custom as physician-centric doesn’t work in and what cial the sphere of er a given market media networks influence of an could be partnerships sosegment and customer. organized efforts redirecte or patient it is possible to identifygrow in popularity, ingly. d accord- encers local market influA wide range The within those ers exist, making of drivers and influenc- has ACA and the shift in payment It may be possible online communities. models Flexibili increased the burden to identify individua example, marketseach market unique. For ganized ty of customer-facin by specialty or experience varying ls customers, and on providers, orpatient type g roles influencin els of provider s payers to manage lev- challengi consolidation, g their peers in who are truly Facts & Figure ng patient Typically while markets may those organizations have more complex some and more institutio populations. As more formly , companies will resource online, opening affiliated nized customer ns and health uni- sibility orga- shift the s than others, systems amountacross the US, deploying the same feeding of creating digital ad boardsposinstitutions, integrate including are to pay-for-performance models, survey by MedPanel, of a resources to in Seattle content via the or or increasingly worried • According they burgh or wearables as in Pitts(IDNs) and health d delivery networks populatio emerging thought Oklahom areadiscussing leaders. City percent physicians relativeoftotheir systems, physician ns for which they about patient scale, such groups, payers, some with 15 asapps lack a solution market Another market to manage them. and volume contrasts potentialhealth or market archetype may This figure ganizations (ACOs). Accountable Care Or, number on average. be char: acterized of prescriptions, Many patients ber of doctors, demands of patientsThe expectations and tomers, of these providers, organized of potential candidates num- such as by a fragmented patient base, staff theornumber number with News Miami, cusAd and patients of and of patients. where the large the influence of local market strategy payers are increasin By Med government—such In aof patient 38 percent Hispanic openness physicians saymodel, base 42 percent pharma and (ACA) complian as Affordable Care Act ceutical to partnerships with g their panies need flexibility com- t A potential receives fragmented services. not using a wearable pharma- their ce benefi to be innovative solution app could to adjust an able regulations—can or state promotional solutionsmanufacturers to help customer facing not using to offer an opt-in may be develop changing patients also vary from roles to a constantl text messaging market. market to bination . Such solutions include so. y providing marketpl services from doing ace. a comhealth education of quality programs is the brand most With differenti Finding managea specific to an The Apple Watch , data genof. individual’s needs. ble ways to address eration partnerships, are aware g, the types serve• as al resourcin This informati local market differenc arche- with (82 percent) shared investme fuel improved a starting physicians on can nts es can be challeng- in patient support and point conversations are most that familiar ing. We have be customiz can aretors between docadherence, and then on and However, ed physicians increased awarenes addressed this through localPhysicians teams market understa patients, helping patients by setting up challenge prove s andand ensure brand knowledg e and by a 2 to 1 margin. advocacy Fitbit,planning tion better local market to imnd the elements public ed with current . In asatisfi organiza concept perceptio thatand geograph mildly archetypes that simplify the is d payer dominate of their own care y scores and improve their average only the value of the integrate te n. Band The issueapprecia alignmen d, where Microsoft of the not an t doctors patient overall of drive decision ent customer the differ- grow In fact, complian do outcomes. products. reps tocedrive While we have needs. One market, making, will only sense for satisfaction in can enable would make Bajaj observed many of allitwearables ample, ce engagem to deploy for ex- is critical importan because ent. highest may possess are thefewer and Jaideep comexecute portions personal, physicians saypanies meetingr outcomesadherence facing resources customer By Saby Mitra un- tocustome attributes of academic medicala high concentration ts an of two the the clinical on than in a integrate represen Local markets market strategy, and thelocal metrics. prescribe ease of use force. This that havetoan that exertmany greatphywhere panies sales centers examples of com-d pharma important:market rs aremost success still the ACO influence to deal ofthe that have optimized generate. ity for a ACO-like) system dominant decision The keys and control opportun the provider or institution will(or an makers. of data the devices s sales rep access tapped over their utility tion deinnovacommun view be through to tor moreins likely ity, a fully open to creating es.whereas another Commercial “As long as tech companies rare. the orchestra may al sicians continue compani partnersh drivenBy designing integrated strategy are es adoptips en-multiple outsourcing apps address saleshave academic enting tradition challengi to tatecoordiAs compani a local market and canas consumertacng patient differentialwearables faciliBy supplemcenters that cline and the are influentia begin to better and pulling it andpopulatio with digital strategy remain such resourcin l more but orwill visits as model the do diabetes ns, grows rep g rep not through via an by allowing pharma companie sales exert control. g across these products patients.and Another market their vironment markets, marketin Creative approach, companie integrated can boost adherenc president, s to easily eutical person may be influence patient ed ﬁve keys e partnersh nate sales different on-board s can establish and presence of ACOs orchestrator dreps to ” says Jason LaBonte, ips n, byengagem complex, pharmac a fad, customer has pinpoint orZS the beent ed partnersh physicians solutions trust-facing used to help ganizatio pressure tics,or (or ACO-like can they engage ntation: ips if reach, resource that files ’s “But constant manage change zations, impleme that l found and ) pro- tion within under organiZS align toMedPanel. company these patients. their percepwhich, es given a particula example, For companies are products, wearables themselv instance,torecognizi ensure a successfu their focusFor key customers, r market d these on quality ofoutcomes diﬀerentiatemetrics ar-of healthcare recommen The ability performance. patients, and traﬃc to a and controllin ng that health chetype. other stakehold to quickly scaleas part to ﬁnd ways to g costs,20 are affected not ers. medadnews down from willpercent impact on the that nearly uptor with the right have an from lace. apps will be viewed sales rep sponsorship only by biologifixtures.” cal factors, Secure way physician resources in the marketp permanen but also by social an organization and become ement tor rep. website provides Howard s andcomes tals operate andbrand’s Further, s. environm the flexibility to risk manag and senior physician Enter the orchestra factors s, preferably get reimbursed. hospian evolution take ad- market Brock is head of commercial models and tor rep is industry As ofand executivevantage interactions with 25 percent ental settings, a particular opportun shifts toward a pharmaceutical local nearly Senior strategy for Campbell The orchestra rep. This arethe new model company personalized medisalesthe mitigate d Alliance. Additional cine, ity or contributors could do a public-pr for both al and targeted email open rates risk of a negative s leversinclude vate compare market-therapies accountability i- will partnersh of the tradition imporby sales reps, with be reasons, couldsent eﬀectivenes event. be relevant head-ip to s, these For outcomes, identifyg atfunction integrates sales, depart- for emails ncies,Renee Selman, president, patient sent bylevel er salesialforce the comwhenmunity Adheris rep compete of sales rep Health; Andrew Aromando, shape the commerc sales ng outsourci those isand er marketin thought with who aredrive customer-facing gy to to about 8 percent of in much the change VP, business aligned plans. executive development, to vulnerab found that non-writ broader and ing and other le to strategic adopts incentive technolo as it terms. and often MED AD NEWS leverages 30 quarters. ZS also double for physicians tant organization Jeanine O’Kane, managinginVentiv Selling Solutions; hiring proﬁles nnelAUGUST ments and 2015 on rates multicha mindset in the d director, ace Biosector integrate conversi Householder 2; and Leigh ing early to both face-to-f g orchestration. , senior VP chief innovation facilitate an ent. The orchestra are exposed Engage marketand marketofficer, GSW. nnel marketin customer engagem help drive a more who and multicha and Integrating salesthe key to the can plan receiving a detailing to a model d Create boost is tor rep ntally ns – compare ications. ing functions approach and tion model, implement increme commun customer-centric ’s reach, engagement promotio ensive vision the orchestra only one of these realize the beneﬁts, While a comprehimperative to success of g will play a vital role in pharma company Before they can os must integrate nce. marketin is equally to drive and performa is essential, it vision in incremental and the sales team however, pharmac adopt an orempowering that companies of pharma sales sales and marketing and a thoughtful, implement manage the de- orchestration. As a result, beginning using Companies can at the Key to the future the orto involve them chestration model with buy-in from steps.and pace of change across buy-in and marketing maturity need implementation to ensure gree d approach a structured of any , the organize ganization with eutical industry consists of three stakeholder groups. success. on. And key In today’s pharmac model. This approacha traditional sales and is diﬀerentiati rator es success the transform to to ent orchest key stages to implem model g with the tor rep. themselves, compani to diﬀerentiate their sales and mar- How rep into an orchestrareps grow more in- Thrivin rator rep rep model ﬁrst stage, a more orchest the need to integrate interacIn g create to to tions rep orchesabout all the marketin companies look keting organiza impactful customer enables ities for sales and cusand tion, they formed As pharmaceutical customers. This ents The opportun coordinated by specialty tor rep sits at implement sales rep orchestra customer tions with their engagem vary , will orchestra stronger d tration mix. However experience. The dynamic. them to drive rep becomes ﬁrst design integrate channel aﬃnity pharma comfor reps. Com- with physicians. Next, the or- tomer’s the heart of this global sales and mar- must ent strategies the specialty, the marketing technology, report, engagem According to integrated with to inﬂuence fu- no matterespecially those with multiple must also leverage AccessMonitor success more s, multiple n and begins the last stage, panies – the U.S. panies plays a critical role in the keting ﬁrm ZS’s In in their portfolio physicians in As cus- ganizatio about half of e-to-severe restrictions which orchestrator rep model. trend ture marketing tactics.orchestrator of all brands r-facing teams and relatively the full custome multichannel and preferences ents, the rep becomes a placed moderat pharma sales reps in of g engagements decent investment into betomer behavior nnel marketin on visits from g on the the risk of falling multicha 23 percent of more toward digital engagem to run s – camarketin g tes with their digital access in g tac- marketinthey remain tied to the status 2014. This compare os need to grow reps with the and coordina restricted rep e of upcomin pharmac changing hind if By Christiane prescribers who timing and relevanc to adapt to the and equip sales Truelove • chris.truelo s pabilities quo and fail use of alternate [email protected] 2008. a tics. to maximize the of digital resource tor rep marketplace. The explosion directly or indirectly ability channels and help them creater. the orchestra early Implementing transforTest with anteam access to digital relationship with the custome has to some extent organizational , create a reduction in digital model requires experience es also must careful planning contributed to companies of meeting with and involves Pharma companitechnology analytics marPharmaceutical access inphysicians. Instead tion us- mationleadership across sales and nts data and s can simply strong investme such a robust cture to equip the sales team should test sales rep orchestra reps, physician digital sources, ce model before keting organizations and customer, management. an early experien formation through . More than 90 per- infrastru teams. ree view of the change ing sales and gy ent 360-deg a across little ’s engagem digital with nationally or in the in technolo as email or webinars companies have in the U.S. accessaccord- including the physician g. Further, it’s scalinga small team as a test group Still, pharma customers’ cent of doctors marketin a Using stage enables choice but to adapt as their their oﬃces, sales and ne aldesign from with ntation to ion es changed of the highest-pow percent have informat initial impleme t for compani ent calibrate, address - alized arma, and 67 and preferences learn, medicine ered events ip to and hip managem ing to eyeforph nals point importanr relations reimbursement tomake needs leadersh of the easy ganizationa care professio permanently. andBIO ormay arise and custome this shift most that 2015 l intuitive design is imforcing convention issues preferred of U.S. health and that and any leadership.” inaccess, as their system PhilThe event scaling the new The market driversand the most sucbefore featured to digital channels ion from pharma (CRM)for repsadelphia did easily so they can interactive changes notbest away, actually use of strations to use the future are not going take emerging technologiedemonmodel. makeinthe source of informat and place provedof the convencompanies in tion through s being center sort and insights. adapted for health care itself, but uprthe cessful pharma that integrate sales and the evo-National companies. street at the iesnew custome data in extraordina train yourry drivers make and Museum of American ways using will be the ones and empower the orgical capabilit tor a all available Involve These market holograms, ies’ technolo Jewish l History, g eﬀorts into an orchestra that helpvirtual reality, Compan at Klick reps 3D printing, Health’sanalytics sales and large-scale lution of the repin the pharmaceuticalExchange inaugural preferﬁrst-level marketin r rep to drive more impactfu include projection mapping. It is crucial that also must event. The e physicianIdeas n the chestratoons with the customer, greater necessary shift ZS estimates that by reps determin invitation-o event, eﬀec- For many attendees, and champio co-sponsor sales actions tonly overall busis embracePresident edbest by BIO, nextKlick industry. In fact, percent of pharmaeﬀectively interacti the Health, was manager on and better Google andand 60 model toClinton the majortor repAfter Veeva them. es diﬀerentiati will be ences Systems, brought draw. 2020, at least medadnews apologies As compani is orchestra engage gether to- being reps in the U.S. their teams. for on ness performance. ntation visionary tively two hours sales leaders impleme their of late, and ceutical sales with g Clinton focus coach piece the nation’s shouldof the top biopharma The ﬁnalCEOs ent, which includes with marketin work of the Clinton they spoke at ZS, Photo Credit: Joe Schildhorn/B orchestrating Foundation tools and train their reps, andgave managemto explore howd role is an associate principal emerging a shout-out change technologie capabilities, and FA.com enhance to tion easy Saby Mitra Bajaj is chairman of ZS’s board a new, s in outgoing and ﬁeld peers. data small portion orchestra rep ntation BIO can the very in radia President , cally changeand CEO Jim Jaideep training U.S. H-1B andvisa te change the wayahealth make the impleme mindset Today, however orcheswider care program that allows , formerally, is deliv-forgressman the strive to Greenwood ered fostering eutical reps orchestra con- othAddition and foreign like 10 how g and of directors. healthtion care to secure buy-in to apply for large of U.S. pharmac marketinPresident the sales force. companies into contractors g the for representin ated of 8th District work. transnumbers of here, years from now, and even if I’m not extent. While Pennsylvan be incorpor these visas and gave change Bill Clinton, ap- the organiza ia. “He should what I hope would to the fullest billedThe is what as the keya major employer tion model. g tration is rapidly be- opportunity customer-centricnote, be happening.” coming orchestra the the marketin an oxymoron in national a frenzy larg- attracted Clinton’s the local teams often adopt to lay oﬀ 250 tech coverage n mustofengage from politics, whose rarely involve news workers, manageme speech not only went into formatio outlets, severance but other luminaries a moderate Republican,” Clinton g budget: proaches, these nt issues, but touched included Dr. Eric the marketin said. Indian replacemenrelied on training their future “And I appreciated on the Topol, director of est portion of of agriculture as the way we were ts. (Senator Bill Nelson the Scripps Translation able of Florida has mounting challenges poor countries face al Science Institute to work on various things.” called for an investigation of in La Jolla, Calif., On the topic of the abuses of the H-1B ple; and the recent in feeding their peoauthor of “The Patient managing growth visa Ebola epidemic, which Will See You Now” AUGUST 2015 in In raising the numbers program.) shows and one of the keynote a sustainable way, Clinton talked 32 MED AD NEWS luncheon speakers of H-1B visas systemsthe need for establishing healthcare about while he at BIO; Dr. Ezekiel the lessons he learned from The was Emanuel, speaker Clinton intent was president, Clinton said the contrast in African nations without one (in Foundation, which on to beneﬁt biotech for several years and the transforma healthcare reform the fastest-grow and other one case to its neighbors, Nigeria only had was STEM industries of Ebola since it showed to allow talented medicine; Dr. Ron tion of American in the world. ing organization of its type uate students grad- wealthiest Cohen, event co-chair, “It’s a constant challenge to be employed area of the country, up in the incoming chairman manage growth without by U.S. good healthcare, to companies. Replacing which has of BIO, and CEO losing the and workers were U.S. workers with Acorda Therapeuti of able to track down and isolate cs Inc.; Janet Wood- that animated the company in vision contractors, however, “is not the culture cock, director of the ﬁrst I believe place, and what worked tient had been in contacteveryone the pathe is productive for best, I believe, is Evaluation and ResearchCenter for Drug a culture of America over with). the long run.” constant commitmen He joked about the Daniel Kraft, inventor at the FDA; Dr. mission, constant t to the Clinton advised the ing of some words change in the meanand entrepreneur, creativity, and constant corporate leaders in the modern world. and founder of cooperation,” he said. Bioniq “There’s a mountain in the audience that “The best companies “Lee [Segal] stood up on this is focused on enabling Health, which full of social stage and have to do said science evidence and scientiﬁc to pursue three things at once. You’ve got that I was a disruptor, did you ever think driven and integrated connected, data research that shows groups of people would the mission that cine; Bob Hariri, CEO personalized medi- better decisions you got into a disruptor become a popular word? I was make business to in grade school too. Therapeutics; Martine of Celgene Cellular say that with than lone geniuses. And I to manage do in the ﬁrst place. You have me All that got some humility, if was Rothblatt, the bad day-to-day, grades founder in conduct.” the IQs in incoming of Sirius XM Radio; including the this room were translated Positive disruption and management to pounds, the important ﬁre. And the third thing that’s gu- ﬂoor would rus Tom Peters and interdependent world is great, “but in an collapse. But Gary Hamel. to do is we have to where all borders According to Klick keep taking look Clinton pointed out it’s really true.” some time out to CEO Leerom Segal, more “Health and technology as one of the 10 most how Klick was cited around the corner,look down the road and cape the like nets than walls, we can’t esare advancing at intrusion of negative admired corporate to such an exponentia cultures, one of forces. ture. Imagine what think about the fu- very often, just l I think it’s going to as there are no ﬁnal But rived at an amazing rate and we’ve ar- one of the 10 the 10 best employers, and be ries, there are victobest places to work. no ﬁnal defeats.” medadnews their convergence. inﬂection point in counts for Pharma something,” he said, “This Ideas Exchange will that the trend touch on cutting-edg adding TWO EXECUTIVE that has placed shareholde CHANGES AT OCHWW gies that are shaping ideas and technolo- ers over stakeholder the • Bill Mordan is now general counsel and future s (such of digital as health – from 21st employBy Christiane Truelove • [email protected] Ogilvy CommonHea century cures, person- ees) has eroded corporate and corporate secretary of Shire, reporting to lth Worldwide workplace has appointed Michael cultures. He called CommonHea Flemming Ornskov. Mordan alsoMarketing serves out the loopholeCEO lth Payer Zilligen as president in the and of both Ogilvy Ogilvy Healthworld Graham to E g Digital Marketin Interactive and ”role to on“orchestrator nce Sales reps take erie r customer exp deliver superio A 1 june august 5 2 Medicine Avenue Klick Ideas Exchang 3 e powers kickoff of BIO conventi on s STATE OF THE BIOTECH INDUSTRY s PAYER ACCESS s DTC s HBA WOTY COVERAGE s TOP 200 MEDICINES s YEAR AFTER LAUNCH s PHARMA LEADERS OF INNOVATION LIONS HEALTH TAKEWAYS s Ad Close: 5/04/16 Materials Due: 5/11/16 Ad Close: 7/03/16 Materials Due: 7/20/16 october december O 4 People On The Move VP AT HCB HEALTH New CFO, financial teamNEW members, atCHICAGO Purdue Pharma J Greg Niemczyk Payer Marketing, and as a member of the Shiregeneral executive commit-of manager Ogilvy CommonHea Zilligen, lth Specialty Marketing. promoted Amy who tee. He joined Shire from Reckitt mostBenckiser recently held the position Marketing, of president at Ogilvy hands Group plc where he served as the group genreins CommonHealth over to Graham, Specialty CommonHea as he assumes the has joined HCB eral counsel and corporatelth secretary. ean-Jacques “JJ” Charhon has ness joined Worldwide’s payer top leadership role marketing agencies development. Niemczyk Health as a VP, account director/busifor Ogilvy will focus housed in New Jersey. Shire alsoZilligen appointed Michele Galen asclients Purdue Pharma as executive VP and chiefoffi ﬁnanis based out of HCB on helping In his ce, address the strategic care reform; bringing new and implications associated new role, head of Corporate Communications cial oﬃcer. Charhon is responsible for the com-and also shares responsibility for growing Health’s Chicago innovations to the base. the agency’s client with healthHe reports directly access organization’s offering services, Public Affairs, reporting to biosimilars, Ornskov. Galen pany’s ﬁnancial, procurement, and information to agency partner in areas such as patient systems of care, and working closely with Nancy Beesley while real world evidence; Chicago’s and additionallylaboration serves as an extended member technology functions. integration and driving continued with Ogilvy CommonHea “Greg has a tremendous President Al Topin. icut-based collth Market Access, of the Shire executivepayer committee. “JJ is a proven leader with experience in the pharmaceutical, reputation in the group. Galen the network’s Connectpharmaceutical growth industry for sparking more in both the professional most recentlyWith served as athan managing direchealthcare, and technology industries,” says Mark Timney, 25 years of industry experience, segments,” says Kerry and direct-to-patient Zilligen has expansive Hilton, CEO and partner the corporate tor for MPMpertise Capitalinand president and CEO. “His expertise and proven recordHCB of suchealth-careadvisor. arena, on both the knowledge and exof HCB Health. “We Health are impressed began client his and at career service by his accomplishm Both the general counsel andatcommunicacess leading ﬁnance organizations will be a valuable services asset to sides of the business. Ogilvy CommonHea ents in both account and agency managemen lth Worldwide nearly Zilligen Greg Niemczyk tions roles marketing are based atdiscipline Shire’s headquarters Purdue’s growth strategy.” 10 years ago within t, and are fortunate and was instrumental get back to his Chicago the payer that his desire to in helping the agency years. Zilligen will report roots coincided with in Lexington, Mass. Charhon joins Purdue from Cnova, one of the largest Niemczyk global succeed during its directly to Shaun Urban, our growth formative Worldwide, who oversees managing partner eCommerce companies, where he served as executivedirector VP and came to HCB from GSW and its oncology aspirations.” at Ogilvy CommonHea the organization’s payer in the Columbus partner Navicor, as developmen lth marketing, medical groups. • Brian Hilberdink hastbeen given the role chief ﬁnancial oﬃcer, with responsibility for investor relations, senior VP, account education and business teams in the immunology office. His contributions ranged from leading domestic has been , oncology, nephrology, of president,Graham Novo Nordisk Canada Inc.from He planning and external reporting. elevated and global ness that elevated executive VP, director and pain categories ofheld Ogilvy both revenue and of client services, to to generating new the CommonHea position of VP, Before joining Cnova, Charhon worked for four marketing years at lthDiabereputation for Worldwide’s full-service busi-previouslycompany general manager professional advertising andfocusing Market on Access, Novo Hewlett Packard, where he joined as chief ﬁnancial demonstrate oﬃcer of experience spans professional to patient the agencies. His extensive integratedtes Marketing high-science and promotion and specialty areas. and pharmaceuticals operations, strategic In Prior to this role, Brian the PC division before becoming chief operating oﬃcer of En- d ability to identify and decipher communicat to biologics, with aNordisk Canada. planning and new business initiatives her new position, Graham leads all providers and patients. Marketing, expanding ion challenges among for Ogilvy CommonHea Marketing, Novo terprise Services, a $23 billion division of HP. This role followed upon the health-carewas corporate VP, Global group’s therapeutic Before joining GSW lth Specialty Graham breadth and client and Navicor, Niemczyk Nordisk A/S,Ms. and led thehas commercialization eight years at General Electric and four years at Novartis, where been with the network’s roster. Chicago, served as VP, account where he managed specialty agency for 20 years of future director at experience of the company’s insulin portfolio, he held various global ﬁnancial leadership roles of increasing overall client-agency two years and has in the pharmaceutical industry. relationships and developedAbelsonTaylor in more than partner responsible She reports to Darlene development untilCommonHea the responsibility. His last role at Novartis was global head of Busifor Ogilvy new business. from Phase II clinical Dobry, managing lth Worldwide’s medical ketinginand medical first launches Europe andmedia Japan.groups. He also ness Planning, Analysis & Investor Relations. marketing, specialty marhas experience working in the United States Charhon earned his baccalaureate in Math, Physics & Chem34 MED AD where, as director, Brand Management, he istry at the French Lycee of Brussels. He holds a master’sNEWS in AUGUST 2015 led multiple brand teams during a period of business administration from the Universite Libre de Bruxelles significant growth for Novo Nordisk U.S. – Solvay School of Management. In addition to Charhon, Thomas Leggett comes aboard • Julie Monzo has been appointed to the Purdue as treasurer and head of Business Development Finewly created role of senior manager, nance with responsibility for business development opportuGlobal Medical and Development (GMD) nity evaluations, capital markets activities, and management of communications, of Astellas’ corporate aftreasury and insurance operations. fairs department. Monzo will report to AnLeggett joins the company with a broad range of investdrew Lewis, head of communications, GMD, ment banking experience. He was most recently an executive Jean-Jacques “JJ” Charhon and will lead internal and external global director and one of three senior calling oﬃcers leading the communications programs for the funcbiopharmaceutical investment banking coverage eﬀort in the tional groups that comprise GMD, includAmericas at UBS Securities LLC. Prior to UBS, he worked in Dan holds a bachelor of arts degree in accounting from Rutgers ing Clinical Development, Medical Affairs, healthcare investment banking at Lazard Freres & Co. and J.P. University, a J.D. from Boston College Law School, and an LLM Pharmacovigilance, Quality Assurance, and Morgan Securities Inc. Leggett holds a master’s in business ad- in taxation from Boston University Law School. Regulatory Affairs. ministration from The Wharton School and a bachelor of arts Edward Mahony is assuming the role of executive VP for Monzo most recently served as senior degree in economics from Columbia University. Due Diligence & Integration Management, with responsibility manager, enterprise communications and Dan Russo joins the company as tax oﬃcer with responsi- for optimizing the value of potential and completed business public relations at the College of American bility for all tax matters, including business development tax development transactions. He began his career at Purdue in Pathologists. structuring. Russo most recently was VP Tax, Americas for Dia- 1993 as VP and chief ﬁnancial oﬃcer, and was promoted to exgeo; tax director for ITT Corp.; and tax counsel at Xerox Corp. ecutive VP and chief ﬁnancial oﬃcer in 1999. medadnews Health O utcome s By Med Ad New s staff Developi for toda ng value-added y’s empo str wered pa ategies By Amy Parke tient Specialty Pharma/Specialty Biopharma Meeting the challenge of physician In order and patie to the disea successfully impac nt colla boration se journ t outcoand focused on ey. theJust development • Briggs W. Morrison, M.D., has joined Syndax Pharmaceuticals • Robert L. Rosiello was appointed as executive VP and chief fi- biopharmaceutical company does the along the as the patienmes, physicians physician. journey treatments for liver and infl ammatory Inc. as CEO and a member of the board of directors. Michael A. nancial officer at Valeant Pharmaceuticals International Inc. Rosi- commercialization of novel must collab gener Altho t needs al popu ugh support orate with Metzger has become president and chief operating officer. Dr. ello worked 30 years at McKinsey & Company helping healthcare, diseases. technologie lation in smart physicians have from phone adop been quick multiple sourc their patient along Morrison came from AstraZeneca, where he was executive VP of technology and consumer companies deliver growth through bring the s such as FitBit es along to tion for into the same the way, example, adopt technology journ hast,been made chief business offi cer of patien Global Medicines Development and chief medical officer. Metzger M&A and business unit financial performance improvement. As • Bob Goodenow, Ph.D., patien so ey mapp they are , outpa the physi ing approwast’s overall care cian travel illustratesMost recently, Dr. Goodenow joins from Regado Biosciences, where he served as president and senior partner in charge of the global merger practice for the past Huya Bioscience International. plan. To slow to incorporatecing the ach to s a path a hypot help for hetical physi in unde how they intera address this, pharm new at Syndax Huya Bioscience spe- chief business officer realiz CEO through the company’s strategic merger with Tobira Thera- decade, Rosiello led M&A integrations to pharmaceutical, ation,Pharmaceuticals. identify rstand ct with consi cian mean ing and new physicians. a needs to relev U.S., International is a leader derataccelerating journ differinent enabling and global cialtydyna pharmaceutical, and medical device companies peutics Inc. ingfu ion, action the ey which treatin l contein the ant channels mic has channels Just like could encom g a disease. and accep nt conte the evolved will provide development of novel biopharmaceutical product opportunities Europe Syndax is a privately held biopharmaceutical company lever- over the and nt and suppoto obtai tance – pastAsia. n conte pass phase The figure below the patiefor each stage and deca supp where in nt. bette rt de By the ort originating in China. Valeant Pharmaceuticals International is a multinational speaging recent scientific insights on its lead therapeutic candidate s such as in that in each makin withr equip throughou nt with the healthcar awareness, phase the the physi each channel where g it easy – mark For e deliv proper t the journ cialty pharmaceutical company that develops, manufactures and entinostat in the emerging field of immuno-oncology. example, cian to collab etpla ery chro and when delivering appro physician turns ey. patie Norange do markets ce. blindly orate with priate educa nic cond to nts diagn of-patien the physician broad of rpharmaceutical products primarily in • Martin J Birkhofer, M.D., has been appointed chief medical longe ntsasit follow direcpatie ition such osed and Professor Chris McGuigan is now chief scientific officer tional go needs it meekly ts along are more categories eyethrou health, and brand• Charles Stacey, M.D., is now president and CEO of Accera Inc. the tion. – pharm as diabeficerwith ghneurology their journ and ease a Toda of dermatology, likely five majo a will tes menmanager ey. migh Birkhofer joins NuCana from inVentiv Health Clinical, journ r at NuCana. ed generics. y’s patie Before joining Accera, he was a senior investment withto arriv t A informed s TOP 50 PHARMACEUTICAL COMPANIES s COMPANY OF THE YEAR s HBA ANNUAL CONFERENCE PREVIEW Ad Close: 9/09/16 Materials Due: 9/16/16 s AD AGENCY ROUNDTABLE s MOBILE MARKETING s NEW VENTURES Ad Close: 11/09/16 Materials Due: 11/16/16 e at their nts ey, inclu phases in t to enga 1. A the disding appo where he led its global medical and scientific affairs and held the London-based Inventages, one of the world’s largest lifegesciences-about their with disease, int- fraught recognition of : an activ Duke Jr.read is now financial officer of Pulmatrix Inc. title of chief medical officer. Professor McGuigan was the original focused venture capital and private equity firms. Accera clinical-their• William with initia physician e arole y chief l denia ing and in the treat and tomsof the ProTide technology and was professor of medicilack Inc. symp of their inventor Dukemen previously served financial officer ofl,Valeritas stage biotechnology company developing ing therapies for central takeas chief In this possible impact of undenal to a study conditionPulmatrix track chemistry at the Cardiff School of Pharmacy and Pharmaceutiist aand clinical stage company developnervous system disorders. phase they d. Indeed, on socia rstan - biopharmaceutical tion Center, published by l cal acco statu arepulmonary rding therapiesand Sciences. He is additionally the chair of the Life Sciences Hub ingthe innovative inhaled to address serious 72 perce Pew Rese diagn reassurance andseeking informa-s. Inter nt ofdisease net indic Wales Ltd. its patented technology. • Iain Ross has been appointed acting chief executive and has arch iSPERSEosis peopusing news outlesites, their frienmay turn to selfle ated line NuCana is a rapidly growing, clinical stage biopharmaceutical been reappointed to the board of Novogen Ltd.for Ross is currently that they using the ds healt ts, and h infor looked Ph.D., is now fami 2. AVP, patient andand perceknown lies, with a broad development portfolio of novel anti-candiagn company • Ian investor relations chairman of Premier Veterinary Group PLC70 (formerly as Ark mati onlincornt of U.S. on Clements, osis and e forum in 2012 on- phase, at least treat again at Tobira Therapeutics Inc. men Dr. Cle- cers.medicines. The company’s proprietary ProTide technology has Therapeutics PLC), a non-executive director of Amarantus Biosci-adulporate and lack one healt ts saycommunications, wher t influ on they h indicments there is com- ence of relations the for Anatara Lifetrack understan the potential to set new benchmarks in efficacy and safety with its previously led investor ande corporate ence Holdings Inc., and a non-executive director ator. Phys denial and r hand peer press pressed othe ding was icians, Pharmaceuticals withrecently that are specifically designed to overcome key cancer sciences Ltd., Benitec Biopharma Ltd. and Tissue Therapies Ltd., overb a for rampedtreatments urdenedat Avanir andwhich best cour ure Inc., time and munications disea inde se up and Pharmaceutical mechanisms. clinical stage resistance Novogen is a public, Australian-U.S. drug-development company. acquired seCo. managem outco by Otsuka of Tobira is a cisiv enes working actio mes-base s pharmace ent, are with their n. Here patie on the resources, utical industry looking to d tion webs nts are physician the or ites , informatients need direction and to provide insurance and possibly the men their prove their to best man education t optio company on poss employer paage and/ ible treat 3. A decisns. Addressincondition. or imare work ion making cant chall g this dilem phas ing with phys with these enge to the ma is a signi their phys e where they fi- to ician’s office ician and burdened empowered industry. Face staff better patients d understan as well as webs the no longe physicians, and over- and its side d ites ily their the r treatmen understan find ways mandate treat industry can changes theyeffects as well t emb as the lifest may need itself and to bridge exist ment but must might be race basicdable. To do so, yle to we need learn it serve the physicianing gaps between how to get addressing needmake. Patients as those in to the follo ing principles s. educated le properly Equally all parti True colla s and patie 4. An Initia such wing chec at hom phobia or important bora nts corre e. our audi address the change es will be need tion between begins perh tion phase wher to health klist, and wher ct content is ence throu the conv ed aps reluc literacy e treat connectincreating the e they ghout their value adde ersation to ultimately tient deals with lack tantly, and thement Checklist journey. of mation. Thiswould most likelyg to people to deliv or and need d strategies of nurs pa- of heal for impr can rang that patie er the on at-home educ seek infor in their ovin manage to better unde th infor ation. Quese follow up disease e mation g the usability their disea rstand, nts want and disease physician’s officefrom brochure prog track and websites online suppression and tions arise s se. to bran • Iden forms. peer tify the ort is often s’ advic Creating 5. An Each chan and social med d and • Use preinten e content, the pati nel will ia platphase wheradherence and sought. and post ded user • Limi ent jour within tailored to engarequire its own ney map face fatigue e those using injecmanagement • Use t the number tests s In orde that r plain ure 1 dem channel envirge the patie tables often bile apps and adherenc between to foster a colla • Practice languageof messages onment. nt activities onstrates the borative respect and the for tracking e drops off. MoFig• Focu pursue all parties, the spiri may patient a 2017 accomost likely to patient outreach • Checks on behavior looks for be employed and use holistic appr industry needs t port from increase rding for und oach to emot careg to advic issued • Suppleme erstandin it comm this approach treat in 2012 to a Cutting Edgethrough e forum ivers, friends ional supas a basis ment unicates sona – nt g s. • a comb and patie Use a med with pictu report l and sician. Dise to both for how nt emphasis digital conta ination of peror translatoically train res body and ase impacts patient and phy- The righ cts with on apps ed inter t content far more r As the a heavy . preter A case sis to curethe patient alone than the in the righ in poin current U.S populatio t is the Understan t place low, developed lows a reall or end of life, . From diagn baby boom n matu oding reach the patie Control by the Centflyer shown and devia y long road be- cial activities will ers are repla res and nt fol- patients go throuthe steps and – the flyer and Preventio ers for Dise media and diagn incorpora ced, outemot gh style, by tions; one chanone with bum ase n. employ ps the osis and treat in dealing with ions grap income, ged by simple Not only does er, more conv texting, requ te more sohard, perso hics discussion learn ment helps by their iring a shor ersat was deve to illustrate thelanguage and use dynamic nal stuff family dynamic. ing ment and to fram as such tto enga ional communica loped in and must main poin e It’s dress of much more lead to the . ge the patie mult develop- support all tion be treat In orde valuable nt. ed Once ing patient demogra iple languagests, it Harnessi r Unit conte to with mean concerns ed State phic grou respond nt ng tech to creat s. at each adps in the patients’ appropria nology tered, aggreed, it shou pharma ingful tools step. lives easi ld be to make tely and er the emotneeds to captu conversation, ingful way) gated and colla curated (filAs show the disea ional and physre data on both out the varioand then synd ted in a mean icated throu embrace n in the chart us chan wher ney. Aspese all along the ical impacts below, the race of migh ever patients nels to offer expo ghcare is technology to patient’s diet and cts such as and their t turn sure jourmed cial med on. Informati improve healt to caregivers lifestyle exercise regim ical routines, However,for education ve webs hia platf and on custo ens, orms ites, creat supp smar to ms, key well as , work dissemina ing soort. impact relationsh and and tronic tphones, note the use of apps te, conte the right conte on the patie should devic understan ips, nt that be AppleWa es such asbooks and elecis enga nt dable, lyzed. Fromcarefully mon nt’s self wortas Indeed, the tch are h a long pharmacecan be a chall ging creating FitBit and the this data, itored and patient new optio utical indu enge. histo anajourn like contr ry of creat ns for into a conc ey map thatone can creat ing ads stry has e acts, webs that Such map ise, visually distills insig a social med ites that compelling hts antiPatient ia look like look assistance that patie s highlight the social interfaces that ads, story dosing programs email 11% taking nts will go throudifferent stage . erally need and using langu are actually Education 5% action Patient s a phys al s thou age that gh from website support to disease. groups 11% As such finally managingbefore deve gh much conteician to interpret.gen11% , patient loped nt journey their vironmen to address creation has AlText messages Patient advocacy been maps the 6% groups 6% do much t in which we regulatory 38 MED ento make AD NEWS oper Reminder our conte ate, we can AUGUST calls 2015 11% nt more read- 36 MED AD NEWS AUGUST 2015 Apps 39% PharmaLive.com returns as the pharmaceutical industry’s #1 destination for news and analysis and delivers the most comprehensive and collaborative community for pharmaceutical marketing professionals. PharmaLive.com offers sleek and reliable navigation and the ability to share, comment and contribute content. Covering ... • Business • Marketing & Advertising • Therapeutics • R&D • Resources es: File Siz ., x 50k ma s 4 frame max., g: Loopin x ma 3 loops Ad units: • Interstitial – 640x480 pixels / $2200 net/week • Rectangle – 300x250 / $2500/mo • Charter Program – 728x90 Leaderboard and Footer, 300x250 Rectangle / $4400/mo Accep ted GIF, An Formats: imate JPEG, H d GIF, T Flash, U ML, nicas PointR oll, Eye t, blas Enliven , Bluest ter, Motif, V reak, ideo Rich M e accept dia is ed for a n additio nal $50 0 Daily Advantage – 20,000 Distribution The PharmaLive Daily Advantage eNewsletter is the most relied on daily news source in the pharmaceutical industry, providing 20,000+ readers with the day’s most important news and information. Leaderboard - $6500/month Rectangle - $4500/month Anchor - $3950/month Featured Company - $2500/month Medicine Ave News (Weekly) Covering all the latest happenings within the healthcare communications world, including agency perspectives, upcoming events and game-changing developments impacting healthcare marketing. 15,000 weekly Leaderboard - $3100/month Rectangle - $2200/month Featured Company - $2200/month Med Ad News Digital Edition Med Ad News Digital Edition expands your reach to an additional 20,000 bonus audience via desktop and upgraded mobile format. Enhance with: Video: $800 / Leaderboard: $1200 / Button: $600 Page Views Total Visits Page Views per Visit 306K 17.4K 17.6 New Visitors Avg Visitors per Day Avg Time on Site 11.1K 43.6 5m 9s Custom Email Campaign PharmaLive.com eBlast Marketing program delivers your branded message to your ideal demographic. Target by business type, job function, geography and more. - $450 CPM o ow what t n k ’t n id d “I year, but is h t t c e p ex o omerun. S h a s a w this tinue the n o c o t y happ . tradition” n e e b s a “This h Manny t s e b e h t !” t e y s d r Awa Each year, agency professionals come together to recognize significant contributions to, and celebrate creative excellence in, healthcare communications. On this special evening, more than six hundred industry peers will join Med Ad News in honoring jury-elected nominees and winners in a range of carefully selected award categories. For over twenty-five years, the Manny Awards have paid tribute to the creative work of agencies serving the healthcare market, their people, and their contributions to the industry. mannyawards Thursday, April 21st, 2016 This unique event is one you cannot miss. Include your branding alongside this prestigious event and reach an audience of engaged advertising professionals. Contact your account manager today! mannyawards.com rates and sizes 2O15 1/2 COVER OUTSIDE FLAP LIVE AREA: 5” X 11.5” TRIM: 5.5” X 12” BLEED: 5.75” X 12.25” KING PAGE KING SPREAD LIVE AREA: 10.375” X 14” TRIM: 10.875” X 14.5” BLEED: 11.125” X 14.75” LIVE AREA: 21.25” X 14” TRIM: 21.75” X 14.5” BLEED: 22” X 14.75” 1X 2X 4X 6X 1X 2X 4X 6X $8395 $7800 $7500 $7195 $15,885 $14,700 $13,500 $12,950 1/2 COVER INSIDE FLAP LIVE AREA: 5” X 14” TRIM: 5.5” X 14.5” BLEED: 5.75” X 14.75” 1/2 KING PAGE 1/2 KING SPREAD TRIM: 10.875” X 7.25” BLEED: 11.125” X 7.5” TRIM: 21.75” X 7.25” BLEED: 22” X 7.5” 1X $16,400 2X $15,300 3X $14,700 1X 2X 4X 6X 1X 2X 4X 6X 4X $13,750 $6825 $6500 $6200 $5900 $12,350 $11,175 $9800 $9500 1-SIDE TAB DIVIDER (APRIL) 1X $9000 2X $8500 3X $8300 4X $8000 JUNIOR PAGE JUNIOR SPREAD LIVE AREA: 7.375” X 10.375” TRIM: 7.875” X 10.875” BLEED: 8.25” X 11.125” LIVE AREA: 15.735” X 10.375” TRIM: 15.735” X 10.875” BLEED: 16.078” X 11.125” 1X 2X 4X 6X $6825 $6500 $6200 $5900 1X 2X 4X 6X $12,350 $11,175 $9800 $9500 Why Choose MedAdNews? n Reach senior level pharmaceutical and biotech professionals n Extended reach in print, online, email and event marketing n The industry, your customers and colleagues demand our unparalleled content Outcomes LLC 16 Prospect Road Livingston, NJ 07039 973-507-6701 Outcomes LLC A marketing and media company built to quench the evolving consumption habits of B to B audiences.